Sulfasalazine-Induced Interstitial Fibrosis

Area of Science:

• Pulmonary Medicine
• Gastroenterology
• Pharmacology

Background:

• Sulfasalazine is a widely used medication for inflammatory bowel disease (IBD) with a long history of clinical application.
• While gastrointestinal side effects are common, severe pulmonary complications are considered rare.
• Patients with pre-existing respiratory conditions may be at increased risk for adverse drug reactions.

Observation:

• A patient with chronic obstructive pulmonary disease (COPD) was treated with sulfasalazine for ulcerative colitis.
• The patient developed interstitial fibrosis after 4 months of continuous sulfasalazine therapy.
• This adverse event occurred in a patient undergoing long-term monitoring for their respiratory condition.

Findings:

• The case highlights a rare instance of sulfasalazine-induced interstitial fibrosis.
• The pulmonary toxicity was observed despite the drug's established efficacy in IBD treatment.
• The development of fibrosis suggests a potential idiosyncratic reaction or increased susceptibility in patients with underlying lung disease.

Implications:

• Clinicians should maintain a high index of suspicion for pulmonary adverse effects of sulfasalazine, especially in patients with COPD.
• Early recognition and discontinuation of the drug may be crucial to prevent irreversible lung damage.
• Further research into the mechanisms of sulfasalazine pulmonary toxicity is warranted to identify at-risk populations.